These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
|
(Address of principal executive offices)
|
Zip Code
|
|
(
|
||
|
Registrant’s telephone number, including area code
|
|
Not Applicable
|
||
|
Former name, former address and former fiscal year, if changed since last report
|
||
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
||
|
|
|
|
|
|
Accelerated filer
☐
|
|
Non-accelerated filer
☐
|
Smaller reporting company
|
|
Emerging growth company
|
|
Item 1.
|
Financial Statements
|
|||
|
5
|
||||
|
6
|
||||
|
7
|
||||
|
8
|
||||
|
9
|
||||
|
Notes to Unaudited Condensed Consolidated Financial Statements
|
||||
|
10
|
||||
|
10
|
||||
|
11
|
||||
|
12
|
||||
|
15
|
||||
|
17
|
||||
|
18
|
||||
|
18
|
||||
|
19
|
||||
|
21
|
||||
|
22
|
||||
|
22
|
||||
|
23
|
||||
|
24
|
||||
|
24
|
||||
|
25
|
||||
|
26
|
||||
|
27
|
||||
|
Item 2.
|
28
|
|||
|
Item 3.
|
40
|
|||
|
Item 4.
|
41
|
|||
|
PART II
-
OTHER INFORMATION
|
||||
|
Item 1.
|
42
|
|||
|
Item 1A.
|
42
|
|||
|
Item 2.
|
42
|
|||
|
Item 6.
|
43
|
|||
|
44
|
||||
| ● |
Adjusted Earnings Per Share (Adjusted EPS);
|
| ● |
Free Cash Flow less Product Development Spending;
|
| ● |
Adjusted Contribution to Profit and margin;
|
| ● |
Adjusted Operating Income and margin;
|
| ● |
Adjusted Income Before Taxes;
|
| ● |
Adjusted Income Tax Provision;
|
| ● |
Adjusted Effective Tax Rate;
|
| ● |
EBITDA, Adjusted EBITDA and margin;
|
| ● |
Organic revenue; and
|
| ● |
Results on a constant currency basis.
|
| ● |
Adjusted EPS, Adjusted Contribution to Profit, Adjusted Operating Income, Adjusted Income Before Taxes, Adjusted Income Tax Provision, Adjusted Effective Tax Rate, Adjusted EBITDA, and organic revenue (excluding acquisitions) provide a more comparable basis to analyze operating results and earnings and are measures commonly used by shareholders to measure our performance.
|
| ● |
Free Cash Flow less Product Development Spending helps assess our ability, over the long term, to create value for our shareholders as it represents cash available to repay debt, pay common stock dividends, and fund share repurchases and acquisitions.
|
| ● |
Results on a constant currency basis remove distortion from the effects of foreign currency movements to provide better comparability of our business trends from period to period. We measure our performance excluding the impact of foreign currency (or at constant currency), which means that we apply the same foreign currency exchange rates for the current and equivalent prior period.
|
|
|
July 31, 2022
|
April 30, 2022
|
||||||
|
Assets:
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Accounts receivable, net of allowance for credit losses of $
|
|
|
||||||
|
Inventories, net
|
|
|
||||||
|
Prepaid expenses and other current assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Technology, property and equipment, net
|
|
|
||||||
|
Intangible assets, net
|
|
|
||||||
|
Goodwill
|
|
|
||||||
|
Operating lease right-of-use assets
|
|
|
||||||
|
Other non-current assets
|
|
|
||||||
|
Total assets
|
$
|
|
$
|
|
||||
|
Liabilities and shareholders' equity:
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
|
$
|
|
||||
|
Accrued royalties
|
|
|
||||||
|
Short-term portion of long-term debt
|
|
|
||||||
|
Contract liabilities
|
|
|
||||||
|
Accrued employment costs
|
|
|
||||||
|
Short-term portion of operating lease liabilities
|
|
|
||||||
|
Other accrued liabilities
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Long-term debt
|
|
|
||||||
|
Accrued pension liability
|
|
|
||||||
|
Deferred income tax liabilities
|
|
|
||||||
|
Operating lease liabilities
|
|
|
||||||
|
Other long-term liabilities
|
|
|
||||||
|
Total liabilities
|
|
|
||||||
|
Shareholders’ equity
|
||||||||
|
Preferred stock, $
|
|
|
||||||
|
Class A common stock, $
|
|
|
||||||
|
Class B common stock, $
|
|
|
||||||
|
Additional paid-in-capital
|
|
|
||||||
|
Retained earnings
|
|
|
||||||
|
Accumulated other comprehensive loss, net of tax
|
(
|
)
|
(
|
)
|
||||
|
Less treasury shares at cost (Class A –
|
(
|
)
|
(
|
)
|
||||
|
Total shareholders’ equity
|
|
|
||||||
|
Total liabilities and shareholders' equity
|
$
|
|
$
|
|
||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Revenue, net
|
$
|
|
$
|
|
||||
|
Costs and expenses
|
||||||||
|
Cost of sales
|
|
|
||||||
|
Operating and administrative expenses
|
|
|
||||||
|
Restructuring and related charges (credits)
|
|
(
|
)
|
|||||
|
Amortization of intangible assets
|
|
|
||||||
|
Total costs and expenses
|
|
|
||||||
|
Operating (loss) income
|
(
|
)
|
|
|||||
|
Interest expense
|
(
|
)
|
(
|
)
|
||||
|
Foreign exchange transaction (losses) gains
|
(
|
)
|
|
|||||
|
Gain on sale of certain assets
|
|
|
||||||
|
Other income, net
|
|
|
||||||
|
(Loss) income before taxes
|
(
|
)
|
|
|||||
|
(Benefit) Provision for income taxes
|
(
|
)
|
|
|||||
|
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
|
(Loss) Earnings per share:
|
||||||||
|
Basic
|
$
|
(
|
)
|
$
|
|
|||
|
Diluted
|
$
|
(
|
)
|
$
|
|
|||
|
Weighted average number of common shares outstanding:
|
||||||||
|
Basic
|
|
|
||||||
|
Diluted
|
|
|
||||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
|
Other comprehensive (loss) income:
|
||||||||
|
Foreign currency translation adjustment
|
(
|
)
|
(
|
)
|
||||
|
Unamortized retirement credits, net of tax (expense) of $(
|
|
|
||||||
|
Unrealized (loss) gain on interest rate swaps, net of tax benefit (expense) of $
|
(
|
)
|
|
|||||
|
Total other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
|
Comprehensive (loss) income
|
$
|
(
|
)
|
$
|
|
|||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Operating activities
|
||||||||
|
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
|
Adjustments to reconcile net income to net cash used in operating activities:
|
||||||||
|
Amortization of intangible assets
|
|
|
||||||
|
Amortization of product development assets
|
|
|
||||||
|
Depreciation and amortization of technology, property and equipment
|
|
|
||||||
|
Restructuring and related charges (credits)
|
|
(
|
)
|
|||||
|
Stock-based compensation expense
|
|
|
||||||
|
Employee retirement plan expense
|
|
|
||||||
|
Foreign exchange transaction losses (gains)
|
|
(
|
)
|
|||||
|
Gain on sale of certain assets
|
|
(
|
)
|
|||||
|
Other noncash (credits) charges
|
(
|
)
|
|
|||||
|
Net change in operating assets and liabilities
|
(
|
)
|
(
|
)
|
||||
|
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
||||
|
Investing activities
|
||||||||
|
Product development spending
|
(
|
)
|
(
|
)
|
||||
|
Additions to technology, property and equipment
|
(
|
)
|
(
|
)
|
||||
|
Businesses acquired in purchase transactions, net of cash acquired
|
(
|
)
|
(
|
)
|
||||
|
Proceeds related to the sale of certain assets
|
|
|
||||||
|
Acquisitions of publication rights and other
|
|
(
|
)
|
|||||
|
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
||||
|
Financing activities
|
||||||||
|
Repayments of long-term debt
|
(
|
)
|
(
|
)
|
||||
|
Borrowings of long-term debt
|
|
|
||||||
|
Purchases of treasury shares
|
(
|
)
|
(
|
)
|
||||
|
Change in book overdrafts
|
(
|
)
|
(
|
)
|
||||
|
Cash dividends
|
(
|
)
|
(
|
)
|
||||
|
Impact of tax withholding on stock-based compensation and other
|
(
|
)
|
(
|
)
|
||||
|
Net cash provided by financing activities
|
|
|
||||||
|
Effects of exchange rate changes on cash, cash equivalents, and restricted cash
|
(
|
)
|
(
|
)
|
||||
|
Cash reconciliation:
|
||||||||
|
Cash and cash equivalents
|
|
|
||||||
|
Restricted cash included in Prepaid expenses and other current assets
|
|
|
||||||
|
Balance at beginning of period
|
|
|
||||||
|
Increase/(decrease) for the period
|
|
(
|
)
|
|||||
|
Cash and cash equivalents
|
|
|
||||||
|
Restricted cash included in Prepaid expenses and other current assets
|
|
|
||||||
|
Balance at end of period
|
$
|
|
$
|
|
||||
|
Cash paid during the period for:
|
||||||||
|
Interest
|
$
|
|
$
|
|
||||
|
Income taxes, net of refunds
|
$
|
|
$
|
|
||||
|
|
Class A common stock
|
Class B common stock
|
Additional
paid-in capital
|
Retained
earnings
|
Accumulated other comprehensive loss, net of tax
|
Treasury stock
|
Total
shareholders' equity
|
|||||||||||||||||||||
|
Balance at April 30, 2022
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||
|
Restricted shares issued under stock-based compensation plans
|
|
|
(
|
)
|
|
|
|
|
||||||||||||||||||||
|
Impact of tax withholding on stock-based compensation and other
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Purchases of treasury shares
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Class A common stock dividends ($
|
|
—
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||
|
Class B common stock dividends ($
|
—
|
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||
|
Comprehensive loss, net of tax
|
|
|
|
(
|
)
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||
|
Balance at
July 31, 2022
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||
|
|
Class A common stock
|
Class B common stock
|
Additional
paid-in capital
|
Retained
earnings
|
Accumulated other
comprehensive loss, net of tax
|
Treasury stock
|
Total
shareholders' equity
|
|||||||||||||||||||||
|
Balance at
April 30, 2021
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||
|
Restricted shares issued under stock-based compensation plans
|
|
|
(
|
)
|
(
|
)
|
|
|
|
|||||||||||||||||||
|
Impact of tax withholding on stock-based compensation and other
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Stock-based compensation expense
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Purchases of treasury shares
|
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Class A common stock dividends ($
|
|
—
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||
|
Class B common stock dividends ($
|
—
|
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||
|
Common stock class conversions
|
|
(
|
)
|
|
|
|
|
|
||||||||||||||||||||
|
Comprehensive income, net of tax
|
|
|
|
|
(
|
)
|
|
|
||||||||||||||||||||
|
Balance at
July 31, 2021
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||||||||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Research
(1)
:
|
||||||||
|
Research Publishing
(2)
|
$
|
|
$
|
|
||||
|
Research Solutions
(2)
|
|
|
||||||
|
Total Research
|
|
|
||||||
|
Academic & Professional Learning:
|
||||||||
|
Education Publishing
|
|
|
||||||
|
Professional Learning
|
|
|
||||||
|
Total Academic & Professional Learning
|
|
|
||||||
|
Education Services:
|
||||||||
|
University Services
(3)
|
|
|
||||||
|
Talent Development Services
(3)
|
|
|
||||||
|
Total Education Services
|
|
|
||||||
|
Total Revenue
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
| (3) |
|
|
|
July 31, 2022
|
April 30, 2022
|
Increase/
(Decrease)
|
|||||||||
|
Balances from contracts with customers:
|
||||||||||||
|
Accounts receivable, net
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||
|
Contract liabilities
(1)
|
|
|
(
|
)
|
||||||||
|
Contract liabilities (included in Other long-term liabilities)
|
$
|
|
$
|
|
$
|
|
||||||
| (1) |
|
|
|
July 31, 2022
|
April 30, 2022
|
||||||
|
Operating lease ROU assets
|
$
|
|
$
|
|
||||
|
Short-term portion of operating lease liabilities
|
|
|
||||||
|
Operating lease liabilities, non-current
|
$
|
|
$
|
|
||||
|
Three Months Ended
July 31,
|
||||||||
|
|
2022
|
2021
|
||||||
|
Operating lease cost
|
$
|
|
$
|
|
||||
|
Variable lease cost
|
|
|
||||||
|
Short-term lease cost
|
|
|
||||||
|
Sublease income
|
(
|
)
|
(
|
)
|
||||
|
Total net lease cost
(1)
|
$
|
|
$
|
|
||||
| (1) |
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Weighted-average remaining contractual lease term (years)
|
|
|
||||||
|
Weighted-average discount rate
|
|
%
|
|
%
|
||||
|
Cash paid for amounts included in the measurement of lease liabilities:
|
||||||||
|
Operating cash flows from operating leases
|
$
|
|
$
|
|
||||
|
Fiscal Year
|
Operating Lease
Liabilities
|
|||
|
2023 (remaining 9 months)
|
$
|
|
||
|
2024
|
|
|||
|
2025
|
|
|||
|
2026
|
|
|||
|
2027
|
|
|||
|
Thereafter
|
|
|||
|
Total future undiscounted minimum lease payments
|
|
|||
|
Less: Imputed interest
|
|
|||
|
Present value of minimum lease payments
|
|
|||
|
Less: Current portion
|
|
|||
|
Noncurrent portion
|
$
|
|
||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Restricted Stock
:
|
||||||||
|
Awards granted (shares)
|
|
|
||||||
|
Weighted average fair value of grant
|
$
|
|
$
|
|
||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Weighted average fair value of options on grant date
|
$
|
|
$
|
|
||||
|
Weighted Average Assumptions
:
|
||||||||
|
Expected life of options (years)
|
|
|
||||||
|
Risk-free interest rate
|
|
%
|
|
%
|
||||
|
Expected volatility
|
|
%
|
|
%
|
||||
|
Expected dividend yield
|
|
%
|
|
%
|
||||
|
Fair value of common stock on grant date
|
$
|
|
$
|
|
||||
|
Exercise price of stock option grant
|
$
|
|
$
|
|
||||
|
|
Foreign
Currency Translation
|
Unamortized
Retirement Costs
|
Interest
Rate Swaps
|
Total
|
||||||||||||
|
Balance at
April 30, 2022
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||
|
Other comprehensive (loss) income before reclassifications
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
|
Amounts reclassified from Accumulated other comprehensive loss
|
|
|
|
|
||||||||||||
|
Total other comprehensive (loss) income
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
|
Balance at
July 31, 2022
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||
|
Balance at
April 30, 2021
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
|
Other comprehensive (loss) income before reclassifications
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
|
Amounts reclassified from Accumulated other comprehensive loss
|
|
|
|
|
||||||||||||
|
Total other comprehensive (loss) income
|
(
|
)
|
|
|
(
|
)
|
||||||||||
|
Balance at July 31, 2021
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Weighted average shares outstanding
|
|
|
||||||
|
Shares used for basic (loss) earnings per share
|
|
|
||||||
|
Dilutive effect of unvested restricted stock units and other stock awards
|
|
|
||||||
|
Shares used for diluted (loss) earnings per share
|
|
|
||||||
|
Antidilutive options to purchase Class A common shares, restricted shares, warrants to purchase Class A common shares, and contingently issuable restricted stock which are excluded from the table above
|
|
|
||||||
|
|
Three Months Ended
July 31,
|
|||
|
2022
|
||||
|
Charges by Segment:
|
||||
|
Research
|
$
|
|
||
|
Academic & Professional Learning
|
|
|||
|
Education Services
|
|
|||
|
Corporate Expenses
|
|
|||
|
Total Restructuring and Related Charges
|
$
|
|
||
|
Charges by Activity:
|
||||
|
Severance and termination benefits
|
$
|
|
||
|
Impairment of operating lease ROU assets and property and equipment
|
|
|||
|
Acceleration of expense related to operating lease ROU assets and property and equipment
|
|
|||
|
Facility related charges, net
|
|
|||
|
Total Restructuring and Related Charges
|
$
|
|
||
|
•
|
Severance charges of $
|
|
•
|
Impairment charges of $
|
|
•
|
Acceleration of expense of $
|
|
|
April 30, 2022
|
Charges
|
Payments
|
Foreign
Translation
& Other Adjustments
|
July 31, 2022
|
|||||||||||||||
|
Severance and termination benefits
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
|||||||||
|
Total
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
|||||||||
|
|
Three Months Ended
July 31,
|
Total Charges
|
||||||||||
|
2022
|
2021
|
Incurred to Date
|
||||||||||
|
Charges (Credits) by Segment:
|
||||||||||||
|
Research
|
$
|
|
$
|
|
$
|
|
||||||
|
Academic & Professional Learning
|
(
|
)
|
|
|
||||||||
|
Education Services
|
|
(
|
)
|
|
||||||||
|
Corporate Expenses
|
|
(
|
)
|
|
||||||||
|
Total Restructuring and Related Charges (Credits)
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
|
Charges (Credits) by Activity:
|
||||||||||||
|
Severance and termination benefits
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
||||
|
Impairment of operating lease ROU assets and property and equipment
|
|
|
|
|||||||||
|
Acceleration of expense related to operating lease ROU assets and property and equipment
|
|
|
|
|||||||||
|
Facility related charges, net
|
|
|
|
|||||||||
|
Other activities
|
|
|
|
|||||||||
|
Total Restructuring and Related Charges (Credits)
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
|
|
April 30, 2022
|
(Credits)
|
Payments
|
Foreign
Translation
& Other Adjustments
|
July 31, 2022
|
|||||||||||||||
|
Severance and termination benefits
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||
|
Total
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||
| ● |
Research
|
| ● |
Academic & Professional Learning
|
| ● |
Education
Services
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Revenue:
|
||||||||
|
Research
(1)
|
$
|
|
$
|
|
||||
|
Academic & Professional Learning
|
|
|
||||||
|
Education Services
|
|
|
||||||
|
Total revenue
|
$
|
|
$
|
|
||||
|
Adjusted Contribution to Profit:
|
||||||||
|
Research
(1)
|
$
|
|
$
|
|
||||
|
Academic & Professional Learning
|
|
|
||||||
|
Education Services
(2)
|
(
|
)
|
(
|
)
|
||||
|
Total adjusted contribution to profit
|
|
|
||||||
|
Adjusted corporate contribution to profit
|
(
|
)
|
(
|
)
|
||||
|
Total adjusted operating income
|
$
|
|
$
|
|
||||
|
Depreciation and Amortization:
|
||||||||
|
Research
(1)
|
$
|
|
$
|
|
||||
|
Academic & Professional Learning
|
|
|
||||||
|
Education Services
(2)
|
|
|
||||||
|
Total depreciation and amortization
|
|
|
||||||
|
Corporate depreciation and amortization
|
|
|
||||||
|
Total depreciation and amortization
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
US GAAP Operating (Loss) Income
|
$
|
(
|
)
|
$
|
|
|||
|
Adjustments:
|
||||||||
|
Restructuring and related charges (credits)
(1)
|
|
(
|
)
|
|||||
|
Accelerated amortization of an intangible asset
(2)
|
|
|
||||||
|
Non-GAAP Adjusted Operating Income
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
|
|
July 31, 2022
|
April 30, 2022
|
||||||
|
Finished goods
|
$
|
|
$
|
|
||||
|
Work-in-process
|
|
|
||||||
|
Paper and other materials
|
|
|
||||||
|
Total inventories before estimated sales returns and LIFO reserve
|
$
|
|
$
|
|
||||
|
Inventory value of estimated sales returns
|
|
|
||||||
|
LIFO reserve
|
(
|
)
|
(
|
)
|
||||
|
Inventories, net
|
$
|
|
$
|
|
||||
|
|
April 30, 2022
|
Foreign
Translation
Adjustment
|
July 31, 2022
|
|||||||||
|
Research
(1)
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
|
Academic & Professional Learning
|
|
(
|
)
|
|
||||||||
|
Education Services
(2)
|
|
(
|
)
|
|
||||||||
|
Total
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
| (1) |
|
| (2) |
|
|
|
July 31, 2022
|
April 30, 2022
(1)
|
||||||
|
Intangible assets with definite lives, net:
|
||||||||
|
Content and publishing rights
|
$
|
|
$
|
|
||||
|
Customer relationships
|
|
|
||||||
|
Developed technology
|
|
|
||||||
|
Brands and trademarks
(2)
|
|
|
||||||
|
Covenants not to compete
|
|
|
||||||
|
Total intangible assets with definite lives, net
|
|
|
||||||
|
Intangible assets with indefinite lives:
|
||||||||
|
Brands and trademarks
|
|
|
||||||
|
Publishing rights
|
|
|
||||||
|
Total intangible assets with indefinite lives
|
|
|
||||||
|
Total intangible assets, net
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Service cost
|
$
|
|
$
|
|
||||
|
Interest cost
|
|
|
||||||
|
Expected return on plan assets
|
(
|
)
|
(
|
)
|
||||
|
Amortization of prior service cost
|
(
|
)
|
(
|
)
|
||||
|
Amortization of net actuarial loss
|
|
|
||||||
|
Net pension income
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
|
July 31, 2022
|
April 30, 2022
|
||||||
|
Short-term portion of long-term debt
(1)
|
$
|
|
$
|
|
||||
|
Term loan A - Amended and Restated RCA
(2)
|
|
|
||||||
|
Revolving credit facility - Amended and Restated RCA
|
|
|
||||||
|
Total long-term debt, less current portion
|
|
|
||||||
|
Total debt
|
$
|
|
$
|
|
||||
| (1) |
|
| (2) |
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Shares repurchased - Class A
|
|
|
||||||
|
Shares repurchased - Class B
|
|
|
||||||
|
Average price - Class A and Class B
|
$
|
|
$
|
|
||||
|
Date of Declaration by
Board of Directors
|
Quarterly Cash Dividend
|
Total Dividend
|
Class of
Common
Stock
|
Dividend Paid
Date
|
Shareholders of
Record as of Date
|
|||||
|
|
$
|
$
|
Class A and Class B
|
|
|
|
Changes in Common Stock A:
|
2022
|
2021
|
||||||
|
Number of shares, beginning of year
|
|
|
||||||
|
Common stock class conversions
|
|
|
||||||
|
Number of shares issued, end of period
|
|
|
||||||
|
Changes in Common Stock A in treasury:
|
||||||||
|
Number of shares held, beginning of year
|
|
|
||||||
|
Purchases of treasury shares
|
|
|
||||||
|
Restricted shares issued under stock-based compensation plans - non-PSU Awards
|
(
|
)
|
(
|
)
|
||||
|
Restricted shares issued under stock-based compensation plans - PSU Awards
|
(
|
)
|
(
|
)
|
||||
|
Restricted shares issued from exercise of stock options
|
|
(
|
)
|
|||||
|
Shares withheld for taxes
|
|
|
||||||
|
Number of shares held, end of period
|
|
|
||||||
|
Number of Common Stock A outstanding, end of period
|
|
|
||||||
|
Changes in Common Stock B:
|
2022
|
2021
|
||||||
|
Number of shares, beginning of year
|
|
|
||||||
|
Common stock class conversions
|
|
(
|
)
|
|||||
|
Number of shares issued, end of period
|
|
|
||||||
|
Changes in Common Stock B in treasury:
|
||||||||
|
Number of shares held, beginning of year
|
|
|
||||||
|
Purchases of treasury shares
|
|
|
||||||
|
Number of shares held, end of period
|
|
|
||||||
|
Number of Common Stock B outstanding, end of period
|
|
|
||||||
| ● |
Research (which was previously referred to as Research Publishing & Platforms)
|
| ● |
Academic & Professional Learning
|
| ● |
Education Services
|
|
•
|
Severance charges of $12.1 million for the elimination of certain positions.
|
|
•
|
Impairment charges of $6.1 million recorded in our corporate category, which included the impairment of operating lease ROU assets of $2.9 million related to certain leases that will be subleased, and the related property and equipment of $3.2 million described further below, and
|
|
•
|
Acceleration of expense of $1.8 million, which included the acceleration of rent expense associated with operating lease ROU assets of $0.9 million related to certain leases that will be abandoned or terminated and the related depreciation and amortization of property and equipment of $0.9 million.
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
US GAAP Operating (Loss) Income
|
$
|
(16,965
|
)
|
$
|
40,968
|
|||
|
Adjustments:
|
||||||||
|
Restructuring and related charges (credits)
|
22,441
|
(276
|
)
|
|||||
|
Accelerated amortization of an intangible asset
(1)
|
4,594
|
—
|
||||||
|
Non-GAAP Adjusted OI
|
$
|
10,070
|
$
|
40,692
|
||||
| (1) |
As described above, we determined that a revision of the useful life of the mthree trademark was warranted and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Net (Loss) Income
|
$
|
(17,835
|
)
|
$
|
13,830
|
|||
|
Interest expense
|
6,332
|
4,639
|
||||||
|
(Benefit) provision for income taxes
|
(5,552
|
)
|
30,172
|
|||||
|
Depreciation and amortization
|
58,279
|
54,566
|
||||||
|
Non-GAAP EBITDA
|
41,224
|
103,207
|
||||||
|
Restructuring and related charges (credits)
|
22,441
|
(276
|
)
|
|||||
|
Foreign exchange transaction losses (gains)
|
616
|
(370
|
)
|
|||||
|
Gain on sale of certain assets
|
—
|
(3,750
|
)
|
|||||
|
Other income, net
|
(526
|
)
|
(3,553
|
)
|
||||
|
Non-GAAP Adjusted EBITDA
|
$
|
63,755
|
$
|
95,258
|
||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
US GAAP (Loss) Income Before Taxes
|
$
|
(23,387
|
)
|
$
|
44,002
|
|||
|
Pretax Impact of Adjustments:
|
||||||||
|
Restructuring and related charges (credits)
|
22,441
|
(276
|
)
|
|||||
|
Foreign exchange losses (gains) on intercompany transactions
|
666
|
(795
|
)
|
|||||
|
Amortization of acquired intangible assets
|
26,385
|
22,284
|
||||||
|
Gain on sale of certain assets
|
—
|
(3,750
|
)
|
|||||
|
Non-GAAP Adjusted Income Before Taxes
|
$
|
26,105
|
$
|
61,465
|
||||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
US GAAP Income Tax (Benefit) Provision
|
$
|
(5,552
|
)
|
$
|
30,172
|
|||
|
Income Tax Impact of Adjustments
(1)
:
|
||||||||
|
Restructuring and related charges (credits)
|
5,517
|
45
|
||||||
|
Foreign exchange losses (gains) on intercompany transactions
|
175
|
(101
|
)
|
|||||
|
Amortization of acquired intangible assets
|
5,832
|
4,843
|
||||||
|
Gain on sale of certain assets
|
—
|
(936
|
)
|
|||||
|
Income Tax Adjustments:
|
||||||||
|
Impact of increase in UK statutory rate on deferred tax balances
(2)
|
—
|
(20,726
|
)
|
|||||
|
Non-GAAP Adjusted Income Tax Provision
|
$
|
5,972
|
$
|
13,297
|
||||
|
US GAAP Effective Tax Rate
|
23.7
|
%
|
68.6
|
%
|
||||
|
Non-GAAP Adjusted Effective Tax Rate
|
22.9
|
%
|
21.6
|
%
|
||||
| (1) |
For the three months ended July 31, 2022 and 2021, substantially all of the tax impact was from deferred taxes.
|
| (2) |
These adjustments impacted deferred taxes in the three months ended July 31, 2021.
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
US GAAP (Loss) Earnings Per Share
|
$
|
(0.32
|
)
|
$
|
0.24
|
|||
|
Adjustments:
|
||||||||
|
Restructuring and related charges (credits)
|
0.30
|
(0.01
|
)
|
|||||
|
Foreign exchange losses (gains) on intercompany transactions
|
0.01
|
(0.01
|
)
|
|||||
|
Amortization of acquired intangible assets
|
0.36
|
0.31
|
||||||
|
Gain on sale of certain assets
|
—
|
(0.05
|
)
|
|||||
|
Income tax adjustments
|
—
|
0.37
|
||||||
|
EPS impact of using weighted-average dilutive shares for adjusted EPS calculation
(1)
|
0.01
|
—
|
||||||
|
Non-GAAP Adjusted EPS
|
$
|
0.36
|
$
|
0.85
|
||||
|
(1)
|
Represents the impact of using diluted weighted-average number of common shares outstanding (56.5 million shares for the three months ended July 31, 2022)
|
|
|
Three Months Ended
July 31,
|
Constant Currency
|
||||||||||||||
|
RESEARCH:
|
2022
|
2021
|
% Change
Favorable
(Unfavorable)
|
% Change
Favorable
(Unfavorable)
|
||||||||||||
|
Revenue:
|
||||||||||||||||
|
Research Publishing
(1)
|
$
|
239,523
|
$
|
243,284
|
(2
|
)%
|
2
|
%
|
||||||||
|
Research Solutions
(1)
|
35,390
|
31,472
|
12
|
%
|
17
|
%
|
||||||||||
|
Total Research Revenue
|
274,913
|
274,756
|
—
|
4
|
%
|
|||||||||||
|
Cost of Sales
|
71,270
|
72,631
|
2
|
%
|
(5
|
)%
|
||||||||||
|
Operating Expenses
|
122,718
|
111,195
|
(10
|
)%
|
(16
|
)%
|
||||||||||
|
Amortization of Intangible Assets
|
11,821
|
11,906
|
1
|
%
|
(4
|
)%
|
||||||||||
|
Restructuring Charges (see Note 9)
|
81
|
216
|
63
|
%
|
63
|
%
|
||||||||||
|
Contribution to Profit
|
69,023
|
78,808
|
(12
|
)%
|
(13
|
)%
|
||||||||||
|
Restructuring Charges (see Note 9)
|
81
|
216
|
63
|
%
|
63
|
%
|
||||||||||
|
Adjusted Contribution to Profit
|
69,104
|
79,024
|
(13
|
)%
|
(13
|
)%
|
||||||||||
|
Depreciation and amortization
|
23,801
|
23,762
|
—
|
(3
|
)%
|
|||||||||||
|
Adjusted EBITDA
|
$
|
92,905
|
$
|
102,786
|
(10
|
)%
|
(9
|
)%
|
||||||||
|
Adjusted EBITDA Margin
|
33.8
|
%
|
37.4
|
%
|
||||||||||||
| (1) |
As previously announced in May 2022, our revenue by product type previously referred to as Research Platforms was changed to Research Solutions. Research Solutions includes infrastructure and publishing services that help societies and corporations thrive in a complex knowledge ecosystem. In addition to Platforms (Atypon), certain product offerings such as corporate sales which included the recent acquisitions of Madgex Holdings Limited (Madgex), and Bio-Rad Laboratories Inc.’s Informatics products (Informatics) that were previously included in Research Publishing moved to Research Solutions to align with our strategic focus. Research Solutions also includes product offerings related to certain recent acquisitions such as J&J, and EJP. Prior period results have been revised to the new presentation. There were no changes to the total Research segment or our consolidated financial results. The revenue reclassified was $20.0 million for the three months ended July 31, 2021, $93.3 million for the year ended April 30, 2022, and $80.3 million for the year ended April 30, 2021.
|
|
|
Three Months Ended
July 31,
|
Constant Currency
|
||||||||||||||
|
ACADEMIC & PROFESSIONAL LEARNING:
|
2022
|
2021
|
% Change
Favorable
(Unfavorable)
|
% Change
Favorable
(Unfavorable)
|
||||||||||||
|
Revenue:
|
||||||||||||||||
|
Education Publishing
|
$
|
63,056
|
$
|
66,380
|
(5
|
)%
|
(2
|
)%
|
||||||||
|
Professional Learning
|
69,903
|
72,884
|
(4
|
)%
|
—
|
|||||||||||
|
Total Academic & Professional Learning
|
132,959
|
139,264
|
(5
|
)%
|
(1
|
)%
|
||||||||||
|
Cost of Sales
|
38,731
|
42,071
|
8
|
%
|
4
|
%
|
||||||||||
|
Operating Expenses
|
90,097
|
85,246
|
(6
|
)%
|
(9
|
)%
|
||||||||||
|
Amortization of Intangible Assets
|
2,756
|
3,624
|
24
|
%
|
22
|
%
|
||||||||||
|
Restructuring Charges (see Note 9)
|
5,790
|
171
|
#
|
#
|
||||||||||||
|
Contribution to Profit
|
(4,415
|
)
|
8,152
|
#
|
#
|
|||||||||||
|
Restructuring Charges (see Note 9)
|
5,790
|
171
|
#
|
#
|
||||||||||||
|
Adjusted Contribution to Profit
|
1,375
|
8,323
|
(83
|
)%
|
(80
|
)%
|
||||||||||
|
Depreciation and amortization
|
16,532
|
18,364
|
10
|
%
|
7
|
%
|
||||||||||
|
Adjusted EBITDA
|
$
|
17,907
|
$
|
26,687
|
(33
|
)%
|
(30
|
)%
|
||||||||
|
Adjusted EBITDA Margin
|
13.5
|
%
|
19.2
|
%
|
||||||||||||
|
|
Three Months Ended
July 31,
|
Constant Currency
|
||||||||||||||
|
EDUCATION SERVICES:
|
2022
|
2021
|
% Change
Favorable
(Unfavorable)
|
% Change
Favorable
(Unfavorable)
|
||||||||||||
|
Revenue:
|
||||||||||||||||
|
University Services
(1)
|
$
|
47,811
|
$
|
54,968
|
(13
|
)%
|
(12
|
)%
|
||||||||
|
Talent Development Services
(1)
|
31,886
|
19,400
|
64
|
%
|
76
|
%
|
||||||||||
|
Total Education Services Revenue
|
79,697
|
74,368
|
7
|
%
|
11
|
%
|
||||||||||
|
Cost of Sales
|
64,030
|
51,252
|
(25
|
)%
|
(29
|
)%
|
||||||||||
|
Operating Expenses
|
21,390
|
19,355
|
(11
|
)%
|
(13
|
)%
|
||||||||||
|
Amortization of Intangible Assets
|
10,613
|
5,622
|
(89
|
)%
|
(90
|
)%
|
||||||||||
|
Restructuring Charges (Credits) (see Note 9)
|
833
|
(34
|
)
|
#
|
#
|
|||||||||||
|
Contribution to Profit
|
(17,169
|
)
|
(1,827
|
)
|
#
|
#
|
||||||||||
|
Restructuring Charges (Credits) (see Note 9)
|
833
|
(34
|
)
|
#
|
#
|
|||||||||||
|
Accelerated amortization of an intangible asset
(2)
|
4,594
|
—
|
#
|
#
|
||||||||||||
|
Adjusted Contribution to Profit
|
(11,742
|
)
|
(1,861
|
)
|
#
|
#
|
||||||||||
|
Depreciation and amortization
|
9,196
|
8,303
|
(11
|
)%
|
(12
|
)%
|
||||||||||
|
Adjusted EBITDA
|
$
|
(2,546
|
)
|
$
|
6,442
|
#
|
#
|
|||||||||
|
Adjusted EBITDA Margin
|
(3.2
|
)%
|
8.7
|
%
|
||||||||||||
| (1) |
In May 2022, we moved the WileyNXT product offering from Talent Development Services to University Services and the prior period results have been included in University Services. The revenue reclassified was $0.6 million for the three months ended July 31, 2021. There were no changes to the total Education Services segment or our total consolidated financial results.
|
| (2) |
On January 1, 2020, Wiley acquired mthree, a talent placement provider that addresses the IT skills gap by finding, training, and placing job-ready technology talent in roles with leading corporations worldwide. Its results of operations are included in our Education Services segment. In late May 2022, Wiley renamed the mthree talent development solution to Wiley Edge and discontinued use of the mthree trademark during the three months ended July 31, 2022. As a result of these actions, we determined that a revision of the useful life was warranted, and the intangible asset was fully amortized over its remaining useful life resulting in accelerated amortization expense of $4.6 million in the three months ended July 31, 2022.
|
|
Metric
|
Fiscal Year 2022 Actual
(1)
|
Fiscal Year 2023 Outlook
At constant currency
(1)
|
FX Impact
At Q1 average rates
(2)
|
Fiscal Year 2023 Outlook
At Q1 average rates
(3)
|
||||
|
Revenue
|
$2,083
|
$2,175 to $2,215
|
$(50)
|
$2,125 to $2,165
|
||||
|
Adjusted EBITDA
|
$433
|
$425 to $450
|
Immaterial
|
$425 to $450
|
||||
|
Adjusted EPS
|
$4.16
|
$3.70 to $4.05
|
Immaterial
|
$3.70 to $4.05
|
||||
|
Free Cash Flow
|
$223
|
$210 to $235
|
Immaterial
|
$210 to $235
|
|
(1)
|
Based on fiscal year 2022 average rates of 1.15 euro and 1.36 British pound.
|
|
(2)
|
Variance between fiscal year 2022 average rates and first quarter fiscal year 2023 average rates: 1.04 euro and 1.23 British pound.
|
|
(3)
|
Fiscal year 2023 outlook at first quarter fiscal year 2023 average rates.
|
|
•
|
Revenue Outlook:
We expect mid-single digit growth at constant currency driven by Research and corporate Talent Development in Education Services.
|
|
•
|
Adjusted EBITDA Outlook:
Adjusted EBITDA at constant currency is expected to be in the range of $425 and $450 million. Solid revenue growth and restructuring savings will be partially offset by targeted investments in Research Publishing, Research Solutions, and corporate Talent Development in Education Services, as well as higher employee costs overall.
|
|
•
|
Adjusted EPS Outlook:
Adjusted EPS at constant currency is expected to be in the range of $3.70 to $4.05. In addition to targeted investments and wage inflation, we expect higher interest expense, higher tax expense, and lower pension income. As previously disclosed, these three items are expected to account for 35-cents of additional adverse impact. Our adjusted effective tax rate is expected to rise this year from 20% to between 22% and 23%. This is primarily due to a less favorable mix of earnings by country and an increase in the UK statutory rate. In terms of the lower pension income, it's important to note that our pensions have been frozen since 2015 and we are above 90% funded.
|
|
•
|
Free Cash Flow Outlook:
Free Cash Flow is expected to be in the range of $210 and $235 million. Positive cash earnings and lower incentive payouts for Fiscal 2022 performance are expected to be offset by higher cash taxes, interest, and capital expenditures. Capital expenditures of $115 to $125 million compared to $116 million in the prior year. Capital investment will be focused on platform and product development in our core growth areas of Research and corporate Talent Development in Education Services.
|
|
•
|
In terms of our
outlook
including FX, currency remains a headwind at the revenue line but since most of our global business is denominated in US dollars, and given our large expense base in Europe, we are largely-self hedged from an earnings and cash flow standpoint.
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Net cash used in operating activities
|
$
|
(89,939
|
)
|
$
|
(84,774
|
)
|
||
|
Net cash used in investing activities
|
(21,806
|
)
|
(23,532
|
)
|
||||
|
Net cash provided by financing activities
|
117,989
|
99,089
|
||||||
|
Effect of foreign currency exchange rate changes on cash, cash equivalents and restricted cash
|
$
|
(1,985
|
)
|
$
|
(1,586
|
)
|
||
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Net cash used in operating activities
|
$
|
(89,939
|
)
|
$
|
(84,774
|
)
|
||
|
Less: Additions to technology, property and equipment
|
(17,923
|
)
|
(17,910
|
)
|
||||
|
Less: Product development spending
|
(5,825
|
)
|
(5,670
|
)
|
||||
|
Free cash flow less product development spending
|
$
|
(113,687
|
)
|
$
|
(108,354
|
)
|
||
|
Net cash used in operating activities – Three months ended July 31, 2021
|
$
|
(84.8
|
)
|
|
|
Net income adjusted for items to reconcile net income to net cash used in operating activities, including the following noncash items: depreciation and amortization, and the change in deferred taxes
|
(36.1
|
)
|
||
|
Working capital changes:
|
|
|||
|
Accounts payable and accrued royalties
|
(14.9
|
)
|
||
|
Accounts receivable, net and contract liabilities
|
25.3
|
|||
|
Changes in other assets and liabilities
|
20.5
|
|||
|
Net cash used in operating activities – Three months ended July 31, 2022
|
$
|
(90.0
|
)
|
|
|
Three Months Ended
July 31,
|
|||||||
|
2022
|
2021
|
|||||||
|
Shares repurchased – Class A
|
212
|
129
|
||||||
|
Shares repurchased – Class B
|
—
|
1
|
||||||
|
Average price – Class A and Class B
|
$
|
47.12
|
$
|
56.88
|
||||
|
|
July 31, 2022
|
April 30, 2022
|
||||||
|
Increase in Inventories, net
|
$
|
7,455
|
$
|
7,820
|
||||
|
Decrease in Accrued royalties
|
(4,072
|
)
|
(3,893
|
)
|
||||
|
Increase in Contract liabilities
|
29,647
|
31,135
|
||||||
|
Print book sales return reserve net liability balance
|
$
|
(18,120
|
)
|
$
|
(19,422
|
)
|
||
|
|
Total Number
of Shares
Purchased
|
Average
Price Paid
Per Share
|
Total Number
of Shares Purchased
as part of a Publicly
Announced Program
|
Maximum Number
of Shares that May
Be Purchased
Under the Program
|
Maximum Dollar
Value of Shares
that May Yet Be Purchased
Under Additional Plans or Programs
(Dollars in millions)
|
|||||||||
|
May 2022
|
—
|
$
|
—
|
—
|
—
|
$
|
197.5
|
|||||||
|
June 2022
|
105,421
|
47.53
|
105,421
|
—
|
192.5
|
|||||||||
|
July 2022
|
106,789
|
46.72
|
106,789
|
—
|
187.5
|
|||||||||
|
Total
|
212,210
|
$
|
47.12
|
212,210
|
—
|
$
|
187.5
|
|||||||
|
Articles of Incorporation and By-Laws
|
|
|
3.1*
|
Restated Certificate of Incorporation of John Wiley and Sons, Inc. July 1, 1992.
|
|
Material Contracts
|
|
|
10.1*
|
Form of the Fiscal Year 2023 Executive Annual Incentive Plan.
|
|
10.2*
|
Form of the Fiscal Year 2023 Executive Long Term Incentive Plan.
|
|
10.3*
|
Restricted Share Unit Grant Agreement Under the Executive Long-Term Incentive Plan, Under the Business Officer Equity Program Pursuant to the 2014 Key Employee Stock Plan.
|
|
10.4*
|
Performance Share Unit Grant Agreement Under the Executive Long-Term Incentive Plan, Under the Business Officer Equity Program Pursuant to the 2014 Key Employee Stock Plan.
|
|
Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
Inline XBRL
|
|
|
101.INS*
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
|
|
101.SCH*
|
Inline XBRL Taxonomy Extension Schema Document.
|
|
101.CAL*
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF*
|
Inline XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.LAB*
|
Inline XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE*
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
|
JOHN WILEY & SONS, INC.
|
|||
|
Registrant
|
|||
|
By
|
/s/ Brian A. Napack
|
||
|
Brian A. Napack
|
|||
|
President and Chief Executive Officer
|
|||
|
By
|
/s/ Christina Van Tassell
|
||
|
Christina Van Tassell
|
|||
|
Executive Vice President and Chief Financial Officer
|
|||
|
By
|
/s/ Christopher F. Caridi
|
||
|
Christopher F. Caridi
|
|||
|
Senior Vice President, Global Corporate Controller and Chief Accounting Officer
|
|||
|
Dated: September 7, 2022
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|